期刊文献+

抗凝溶栓重组葡激酶-水蛭素融合蛋白的构建与表达 被引量:1

下载PDF
导出
摘要 目的:探讨抗凝溶栓重组葡激酶-水蛭素融合蛋白的构建效果与抗凝溶栓活性表达情况。方法:在间接实验中,选择p BV-重组葡激酶-水蛭素融合蛋白质质粒进行酵母大量表达,再进行两级纯化分析;去纯化的单位进行抗凝溶栓的检测。结果:工程菌酵母发酵培养诱导1 h后就可以检测到重组葡激酶-水蛭素融合蛋白表达,表达量随发酵时间的增加而递增。两级纯化的重复性非常好,纯度经RP-HPLC测定在98%以上。重组葡激酶-水蛭素融合蛋白的溶栓活性明显高于水蛭素与葡激酶的单纯溶栓活性(P<0.05)。重组葡激酶-水蛭素融合蛋白具有更强的纤溶酶原激活活性,明显高于水蛭素与葡激酶的单纯纤溶酶原激活活性(P<0.05)。结论:重组葡激酶-水蛭素融合蛋白生产工艺具有很好的诱导与纯化效果,重组葡激酶-水蛭素融合蛋白能发挥较好的抗凝与溶栓作用。
出处 《内科急危重症杂志》 2015年第2期138-140,共3页 Journal of Critical Care In Internal Medicine
基金 湖北省教育厅课题(No:B2013105)
  • 相关文献

参考文献10

  • 1Fitchett D. Tailored antithrombotic therapy for acute coronary syn- dromes[ J]. Expert Rev Cardiovasc Ther,2008,6(8 ) :935-944.
  • 2Lian Q, Szarka SJ, Ng KK, et al. Engineering of a staphylokinase- based fibrinolytic agent with antithrombotic activity and targeting ca- pability toward thrombin-rich fibrin and plasma clots [ J ]. J Biol Chem,2013,278( 11 ) :26677-26686.
  • 3胡枢坤,吴靖宇,黄峰平.凝血酶在脑出血后脑损伤过程中促进细胞自噬性死亡的研究[J].中华实验外科杂志,2014,31(2):322-324. 被引量:5
  • 4Sheffield WP, Eltringham-Smith LJ, Gatalance S, et al. A long-lasting, plasmin-activatable thrombin inhibitor aids clot lysis in vitro and does not promote bleeding in vivo [ J ]. Thromb Haemost, 2009,101 (8) : 867 -877.
  • 5邓国彤,梁少瑜,吴燕梅,宋国强,沈志滨.抗凝血酶滴定法优化水蛭煮散提取工艺[J].中国实验方剂学杂志,2014,20(17):10-13. 被引量:5
  • 6Szemraj J,Zakrzeska A,Brown G,et al. New derivative of staphyloki- nase SAK-RGD-K2-Hirul exerts thrombolytic effects in the arterial thrombosis model in rats [ J ]. Pharmacol Rep, 2011,63 ( 5 ) : 1169- 1179.
  • 7韦淑怡,殷国前,韩志强,潘新元,林博杰.天然水蛭素水凝胶的皮肤渗透性能及毒理学考察[J].中国实验方剂学杂志,2014,20(9):5-8. 被引量:4
  • 8Kumar A, Pulicherla KK, Mayuren C, et al. Evaluation of a multifhnc- tional staphylokinase variant with thrombin inhibition and antiplatelet aggregation activities produced from salt-inducible E. coli GJl158 [ J]. Can J Physiol Pharmacol,2013,91 (10) :839-847.
  • 9龙民慧,王园园,朱贺,王曼,邹民吉,马百坤,王嘉玺,徐东刚.融合蛋白P11-A1的构建、表达及生物活性研究[J].军事医学科学院院刊,2008,32(6):511-514. 被引量:1
  • 10Zhang CL,Yu AP,Yuan B,et al. Construction and functional evalua- tion of hirudin derivatives with low bleeding risk [ J ]. Thromb Haem- ost,2008,99( 11 ) :324-330.

二级参考文献63

  • 1洪震.脑卒中的流行病学及其危险因素[J].中国卒中杂志,2006,1(8):559-563. 被引量:37
  • 2曾非,余绍祖,陈谦学.凝血酶诱导皮质神经元凋亡及其机制研究[J].中华实验外科杂志,2004,21(12):1508-1510. 被引量:5
  • 3马百坤,郭利利,方蓉,徐东刚.人载脂蛋白AⅠ基因的克隆表达及功能[J].中国生物化学与分子生物学报,2005,21(2):273-277. 被引量:3
  • 4庄一义.载脂蛋白A1和B的参考值及临床意义[J].中国动脉硬化杂志,2006,14(3):263-266. 被引量:35
  • 5Phillips MC, Gillotte KL, Haynes MP, et al. Mechanisms of high density lipoprotein mediated efflux of cholesterol from cell plasma membranes[ J]. Atherosclerosis, 1998, 137 (Suppl) : 13 - 17.
  • 6Eriksson M, Carlson LA, Miettinen TA, et al. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein AI. Potential reterse cholesternl transport in humans [ J]. Circulation, 1999, 100 (6) : 594 -598.
  • 7Francis GA, Tsujita M, Terry TL, et al. Apolipoprotein AI efficiently binds to and mediates cholesterol and phospholipid efflux from human but not rat aortic smooth muscle cell[J]. Biochemistry, 1999, 38 (49): 16315-16322.
  • 8Nanjee MN, Cooke CJ, Garvin R, et al. Intravenous ApoA-Ⅰ Plecithin discs increase pre-beta-P, DL concentration in tissue fluid and stimulate reverse cholesterol transport in humans [ J ]. Lipid Res, 2001,42(10) : 1586 - 1593.
  • 9Pastore L, Belalcazar LM, Oka K, et al. Helper-dependent adenoviral vector-mediated long-term expression of human apolipoprotein A-I reduces atherosclerosis in apoE-deficient mice [ J ]. Gene, 2004,327 (2) : 153 -160.
  • 10Belalcazar LM, Merehed A, Carr B, et al. Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atheroselerotic plaques in a mouse model of familial hypereholesterolemia [ J]. Circulation, 2003, 107 ( 21 ) : 2726 - 2732.

共引文献11

同被引文献57

  • 1沈友进,蔡毅,苏庆杰,曾超胜.溶栓药的研究进展[J].临床医学工程,2010,17(6):150-153. 被引量:13
  • 2梅乐和,胡升,许静,姚善泾,郑晓冬.纳豆枯草杆菌的筛选和纳豆激酶发酵条件优化[J].浙江大学学报(工学版),2004,38(10):1355-1360. 被引量:42
  • 3常福厚,齐君,张晓梅,王敏杰,尹琴,扈廷茂.溶栓药替奈替普酶研究进展[J].动物医学进展,2007,28(2):67-69. 被引量:9
  • 4瑞替普酶Ⅱ期临床试验协作组.注射用瑞替普酶(派通欣)治疗急性心肌梗死有效性及安全性临床研究[J]中国心血管病研究杂志,2004(03).
  • 5Boudreau DM,Guzauskas GF,Chen E,et al.Cost-effectiveness of recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke:current evidence[J].Stroke,2014,45(10):3032-3039.
  • 6Bernik MB.Increase plasminogen activator(urokinase)in tissue culture after fibrin deposition[J].J Clin Invest,1973,52(4):823-834.
  • 7Van de Werf F,Nobuhara M,Collen D.Coronary thrombolysis with human single-chain,urokinase-type plasminogen activator(prourokinase)in patients with acute myocardial infarction[J].Ann Intern Med,1986,104(3):345-348.
  • 8FlohéL.Single-chain urokinase-type plasminogen activators:new hopes for clot-specific lysis[J].Eur Heart,1985,6(11):905-908.
  • 9Lijnen HR,Collen D.Mechanisms of plasminogen activation by mammalian plasminogen activators[J].Enzyme,1998,40(2/3):90-96.
  • 10Tebbe U,Michels R,Adgey J,et al.Randomized,double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction:the COMPASS Equivalence Trial[J].J Am Coll Cardiol,1998,31(3):487-493.

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部